The Efficacy of Hand NBUVB Versus Excilite Treatment in Vitiligo After Minigrafting on the Dorsal Hands
The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2008 by University of Texas Southwestern Medical Center.
Recruitment status was Active, not recruiting
Recruitment status was Active, not recruiting
Sponsor:
University of Texas Southwestern Medical Center
Information provided by:
University of Texas Southwestern Medical Center
ClinicalTrials.gov Identifier:
NCT00622180
First received: January 23, 2008
Last updated: January 21, 2009
Last verified: February 2008
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
To assess over a 25-week period the efficacy of hand-foot narrow-band ultraviolet B light versus focal 308-nm light treatment in inducing the return of pigment in vitiligo after skin minigraft transplants to the backs of the hands in patients with light brown to black skin. Subject will undergo treatment for 13 weeks.
| Condition | Intervention |
|---|---|
|
Vitiligo |
Device: Daavlin Spectra UVB Hand/Foot Box Device: Excilite Focal 308-nm light |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Single Blind (Investigator) Primary Purpose: Treatment |
| Official Title: | The Efficacy of Hand-Foot Narrow-Band UVB Versus Focal 308-nm Treatment in Inducing Repigmentation of Vitiligo After Minigrafting on the Dorsal Hands |
Resource links provided by NLM:
Further study details as provided by University of Texas Southwestern Medical Center:
Primary Outcome Measures:
- Percent repigmentation of individual surviving grafts, percent repigmentation of all surviving grafts per hand, and percent repigmentation of lesional skin with each light source. [ Time Frame: 25 weeks ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Time to initial 10% repigmentation per graft, time to initial 10% repigmentation per lesion, the physician global repigmentation assessment, and an assessment of the safety of each treatment. [ Time Frame: 25 weeks ] [ Designated as safety issue: Yes ]
| Estimated Enrollment: | 25 |
| Study Start Date: | January 2008 |
| Estimated Study Completion Date: | April 2009 |
| Estimated Primary Completion Date: | January 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: 1
Right hand treated with narrow-band UVB light and left hand treated with focal 308-nm light
|
Device: Daavlin Spectra UVB Hand/Foot Box
Narrow-band ultraviolet B hand box
|
|
Active Comparator: 2
Right hand treated with focal 308-nm light and left hand treated with narrow-band UVB light
|
Device: Excilite Focal 308-nm light
Excilite Focal 308-nm light
|
Detailed Description:
Prospective investigator-blinded study involving 25 adult male and female subjects with vitiligo on the backs of both hands. Punch minigrafting will be performed on both hands taking skin from the thighs and/or buttocks. Light treatments will be administered starting at week one after grafting. One hand will receive narrow-band ultraviolet B light and the other will receive focal 308-nm light treatments. Light treatments will be administered 3 times per week for 12 weeks. A long term follow-up visit will be completed at week 25. The investigator will evaluate the subjects at week 4, 7, 13 and 25 in addition to screening and baseline evaluations/procedures.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- male and female subjects 18 years of age or older
- skin type III-VI
- vitiligo on both dorsal hands
- history of stable vitiligo ( no new lesions and no more than 10% enlargement of existing lesions) for six months with an absence of Kebner phenomenon (new lesions appearing after trauma to the skin)
- refractory to topical steroids and immunomodulators
Exclusion Criteria:
- pregnant and/or breast-feeding females
- history of skin cancer
- history of taking photosensitizing medications
- history of recent phototherapy (light therapy) or topical medications within one month prior to enrollment
- history of organ transplantation
- history of failed vitiligo skin transplantation
- history of segmental vitiligo
- history of 12 or more continuous light treatments
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00622180
Locations
| United States, Texas | |
| UT Southwestern Medical Center at Dallas - Dermatology Clinical Trials | |
| Dallas, Texas, United States, 75390-8802 | |
Sponsors and Collaborators
University of Texas Southwestern Medical Center
Investigators
| Principal Investigator: | Amit Pandya, M.D. | UT Southwestern Medical Center at Dallas - Department of Dermatology |
More Information
No publications provided
| Responsible Party: | Amit Pandya, M.D. - Professor of Dermatology, UT Southwestern Medical Center at Dallas |
| ClinicalTrials.gov Identifier: | NCT00622180 History of Changes |
| Other Study ID Numbers: | IRB file number 122007-003, 122007-003 |
| Study First Received: | January 23, 2008 |
| Last Updated: | January 21, 2009 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by University of Texas Southwestern Medical Center:
|
Vitiligo Light treatment for vitiligo Excilite |
Additional relevant MeSH terms:
|
Vitiligo Hypopigmentation Pigmentation Disorders Skin Diseases |
ClinicalTrials.gov processed this record on May 19, 2013